ArriVent BioPharma Company Insiders

ArriVent BioPharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.3278) % which means that it has lost $0.3278 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5184) %, meaning that it created substantial loss on money invested by shareholders. ArriVent BioPharma's management efficiency ratios could be used to measure how well ArriVent BioPharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 01/14/2026, Return On Tangible Assets is likely to drop to -0.28. In addition to that, Return On Capital Employed is likely to drop to -0.44. As of 01/14/2026, Total Current Liabilities is likely to drop to about 10.7 M. In addition to that, Liabilities And Stockholders Equity is likely to drop to about 182.6 MAs of 01/14/2026, Common Stock Shares Outstanding is likely to drop to about 27 MArriVent BioPharma holds a total of 41.28 Million outstanding shares. The majority of ArriVent BioPharma Common outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in ArriVent BioPharma Common to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in ArriVent BioPharma. Please pay attention to any change in the institutional holdings of ArriVent BioPharma Common as this could imply that something significant has changed or is about to change at the company. Also note that nearly nine hundred thirty-seven thousand eighty-seven invesors are currently shorting ArriVent BioPharma expressing very little confidence in its future performance. At this time, ArriVent BioPharma's Graham Net Net is relatively stable compared to the past year. As of 01/14/2026, Interest Debt Per Share is likely to grow to 0.01, while Operating Cash Flow Per Share is likely to drop (2.11).

ArriVent BioPharma Workforce Comparison

ArriVent BioPharma Insider Trading

ArriVent BioPharma Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as ArriVent BioPharma Common often depends on how effective the management is. ArriVent BioPharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ArriVent management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ArriVent management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

When running ArriVent BioPharma's price analysis, check to measure ArriVent BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma is operating at the current time. Most of ArriVent BioPharma's value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma's price. Additionally, you may evaluate how the addition of ArriVent BioPharma to your portfolios can decrease your overall portfolio volatility.